Regulus Therapeutics (NASDAQ:RGLS) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Regulus Therapeutics (NASDAQ:RGLS) in a research report released on Wednesday, Benzinga reports. They currently have a $10.00 target price on the biopharmaceutical company’s stock.

Several other brokerages also recently issued reports on RGLS. StockNews.com raised shares of Regulus Therapeutics to a “sell” rating in a report on Tuesday, September 17th. Oppenheimer reissued an “outperform” rating and set a $7.00 price target on shares of Regulus Therapeutics in a report on Wednesday, August 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $10.80.

Regulus Therapeutics Price Performance

Regulus Therapeutics stock opened at $1.56 on Wednesday. The company has a market cap of $102.13 million, a PE ratio of -1.24 and a beta of 1.62. The company has a fifty day moving average price of $1.59 and a two-hundred day moving average price of $1.87. Regulus Therapeutics has a 12 month low of $1.08 and a 12 month high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.17). Equities research analysts anticipate that Regulus Therapeutics will post -0.8 earnings per share for the current year.

Institutional Investors Weigh In On Regulus Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Tyche Wealth Partners LLC raised its position in Regulus Therapeutics by 920.6% in the third quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company’s stock worth $167,000 after acquiring an additional 95,694 shares in the last quarter. Creative Planning bought a new stake in Regulus Therapeutics in the third quarter worth about $26,000. SG Americas Securities LLC bought a new stake in Regulus Therapeutics in the third quarter worth about $33,000. Renaissance Technologies LLC raised its position in Regulus Therapeutics by 56.4% in the second quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 42,600 shares in the last quarter. Finally, Rhumbline Advisers bought a new stake in Regulus Therapeutics in the second quarter worth about $136,000. 92.38% of the stock is currently owned by institutional investors.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.